Endocrine exophthalmos

This study tests an injection called MHB018A for people with moderate-to-severe thyroid eye disease, which can cause bulging eyes and discomfort. About 219 adults who completed an earlier study will receive the drug for 24 weeks to see if it reduces eye bulging and prevents sympt…

This Phase 3 trial tests an injection called MHB018A for people with chronic moderate-to-severe thyroid eye disease. About 135 participants will receive either the drug or a placebo every 4 weeks for 24 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 …

This study tests an injection called MHB018A for people with active moderate-to-severe thyroid eye disease, which causes eye bulging and discomfort. About 84 adults aged 18-75 will receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters ove…

This early-stage trial tests the safety and tolerability of a new drug called IBI3031 in 66 people with moderate-to-severe active thyroid eye disease. Participants will receive either the drug or a placebo by injection or infusion. The study aims to find the right dose and check …

This study compares two treatments given after emergency eye surgery for people with thyroid eye disease who have vision loss. One group gets teprotumumab, a newer drug that blocks a growth factor, and the other gets high-dose steroids. The goal is to see which one better improve…

This early-stage trial tests a new drug called NTB003 in 74 people with thyroid eye disease, a condition that can cause bulging eyes and inflammation. Participants receive injections of NTB003 or a placebo every 4 weeks. The study measures whether the drug reduces eye bulging and…

This study tests a new gene therapy called VV-14305, given as an injection around the eye, for people with moderate to severe thyroid eye disease. The trial will include 110 adults and is split into two parts: first to check safety, then to compare the treatment against a sham in…

This study compares a shortened 4-infusion course of the drug Teprotumumab (Tepezza) against the standard 8-infusion course for people with active thyroid eye disease. Only patients who show a good early response will be eligible for the shorter regimen. The goal is to see if few…

This study tests a new drug called teprotumumab N01 for active thyroid eye disease, which causes eye bulging and discomfort. About 92 adults will receive either the new drug or standard steroid treatment. The main goal is to see if the new drug better reduces eye bulging.

This study will check if an AI system can accurately measure eye movements from smartphone videos. About 1,000 adults with suspected eye movement issues will record a short video while following a moving target. The AI's measurements will be compared to expert ratings to see if i…

This study explores whether a smartphone app using artificial intelligence can help people with thyroid eye disease (TED) monitor their condition from home. Participants take weekly facial photos and answer symptom questions via the app while undergoing standard non-surgical trea…